tretinoin and Hemorrhagic-Fever--Ebola

tretinoin has been researched along with Hemorrhagic-Fever--Ebola* in 1 studies

Other Studies

1 other study(ies) available for tretinoin and Hemorrhagic-Fever--Ebola

ArticleYear
A Luciferase Reporter Gene Assay to Measure Ebola Virus Viral Protein 35-Associated Inhibition of Double-Stranded RNA-Stimulated, Retinoic Acid-Inducible Gene 1-Mediated Induction of Interferon β.
    The Journal of infectious diseases, 2015, Oct-01, Volume: 212 Suppl 2

    During Ebola virus (EBOV) infection, the type I interferon α/β (IFN-α/β) innate immune response is suppressed by EBOV viral protein 35 (VP35), a validated drug target. Identification of EBOV VP35 inhibitors requires a cellular system able to assess the VP35-based inhibitory functions of viral double-stranded RNA (dsRNA) IFN-β induction. We established a miniaturized luciferase gene reporter assay in A549 cells that measures IFN-β induction by viral dsRNA and is dose-dependently inhibited by VP35 expression. When compared to influenza A virus NS1 protein, EBOV VP35 showed improved inhibition of viral dsRNA-based IFN-β induction. This assay can be used to screen for EBOV VP35 inhibitors.

    Topics: Cell Line; Ebolavirus; Genes, Reporter; Hemorrhagic Fever, Ebola; Humans; Interferon-alpha; Interferon-beta; Luciferases; RNA, Double-Stranded; Transcriptional Activation; Tretinoin; Viral Nonstructural Proteins; Viral Proteins

2015